AstraZeneca Annual Report and Directors Remuneration Report 50 Form 20-F Information 2003 Directors Remuneration Report independence of the external auditor At the Annual General Meeting on 29 April shareholder value, is clear about the were not in any way impaired by either 2004, a resolution will be proposed to Companys objectives, knows how their the nature of the non-audit work approve the Directors Remuneration work impacts on those objectives and that undertaken by the external auditor Report.
they will benefit from achieving high levels of during the year, the level of non-audit performance.
fees charged for such work or any other Remuneration Committee facts or circumstances: full details of the The members of the Remuneration The Board has confirmed that the audit and non-audit fees for the year are Committee are Sir Peter Bonfield Chairman Companys overall remuneration policy and disclosed in Note 33 to the Financial of the Committee, John Buchanan and purpose is: Statements: and Erna Mller.
They are all Non-Executive Directors.
The Board considers them all to to attract and retain people of the quality the impact of the US Sarbanes-Oxley be independent.
necessary to sustain the Company as Act of 2002 on the Company and, in one of the best pharmaceutical particular, on the operation of the Audit The remit of the Remuneration Committee companies in the world: and Committee and its relationship with the is, primarily, to recommend for decision by to motivate them to achieve the level of external auditor: this included periodic the Board the fundamental remuneration performance necessary to create reviews of the Companys state of policy for the Company and to ensure the sustained growth in shareholder value.
compliance with applicable provisions proper operation of all plans for employees of the Act.
More In order to achieve this, remuneration policy particularly, it makes specific proposals in and practice is designed: At the scheduled meeting of the Audit respect of the remuneration packages of Committee held at the end of January 2004, individual Executive Directors and the to closely align individual and team the Chief Executive and the Chief Financial Companys most senior executives.
A copy reward with business performance at Officer presented to Audit Committee of the Remuneration Committees remit is each level: members their conclusions following the available on the Companys website: to encourage employees to perform to evaluation of the effectiveness of the astrazeneca.
their fullest capacity: Companys disclosure controls and to encourage employees to align their procedures required by Item 15 a of Form The Remuneration Committee met four interests with those of shareholders: 20-F. Based on their evaluation, the Chief times during 2003.
Each meeting was to support managers responsibility to Executive and the Chief Financial Officer attended by all three of its members.
At the achieve business performance through concluded that the Company maintains an invitation of the Remuneration Committee, people and for them to recognise effective system of disclosure controls and the Chairman of the Board, a Nonsuperior performance, in the short and procedures.
Executive Director, attended all of its longer term: meetings in 2003.
At the request of the to be as locally focused and flexible as is There was no change in the Companys Remuneration Committee, Sir Tom practicable and beneficial: internal control over financial reporting that McKillop, Chief Executive and Peter Brown, to be competitive and cost-effective in occurred during the period covered by this Vice-President, Global Compensation and each of the relevant employment Annual Report and Form 20-F Information Benefits, as well as the Secretary of the markets: and that has materially affected, or is reasonably Remuneration Committee, Graeme Musker, to be as internally consistent as is likely to materially affect, the Companys attended all of its meetings and provided practicable and beneficial taking due internal control over financial reporting.
advice and services which materially account of market need.
assisted the Remuneration Committee On behalf of the Audit Committee during 2003.
In doing so, Mr Brown drew on The cost and value of the components of K M von der Heyden various sources of data concerning the remuneration package are considered Non-Executive Director and directors and executives salaries, bonus as a whole and are designed: Chairman of the Audit Committee levels and other incentives including general 29 January 2004 pharmaceutical industry reports and to ensure a proper balance of fixed and surveys, as well as surveys specifically variable performance-related carried out for the Company.
These components, linked to short and longer included certain surveys prepared for the term objectives: and Company by Towers Perrin.
During 2003, to reflect market competitiveness taking Towers Perrin also provided global share account of the total value of all of the plan administration services to the benefit components.
Company and consultancy services to the Companys US business.
The principal components contained in the total remuneration package, for employees Overall remuneration policy and as a whole, are: purpose The Company is committed to maintaining annual salary based on conditions in a dynamic performance culture in which the relevant geographic market, with the every employee champions the growth of provision to recognise, in addition, the AstraZeneca Annual Report and Directors Remuneration Report Form 20-F Information 2003 51 value of individuals sustained personal above, this is derived from the On death in retirement, the accrued performance, resulting from their ability budget set by the Board and takes pension is guaranteed payable for and experience: into account external expectations the first five years of retirement and annual bonus a lump sum payment of performance: then reduces to two-thirds of this related to the targeted achievement of amount should there be a surviving corporate, functional and individual the Deputy Chairman was also spouse or other dependent: any goals, measured over a year within a eligible for this annual bonus related member may choose higher or specific plan: the corporate goals are solely to earnings per share for that lower levels of survivors pensions at derived from the annual budget set by part of 2003 during which he served retirement, subject to Inland the Board and take into account as an Executive Director 1 January Revenue limits, in return for an external expectations of performance: 2003 until 31 August 2003 : adjustment to their own pension of the functional goals are agreed by the equivalent actuarial value: pensions Remuneration Committee at the start the Chief Financial Officer is eligible are also payable to dependent of, and are monitored throughout, the for an annual bonus related to the children: in the event of a senior year: achievement of both the targeted employee becoming incapacitated longer term incentive for selected performance of earnings per share from performing his work then a groups, a longer term incentive targeted and the achievement of pension is payable immediately as if at the achievement of strategic performance measures relevant to such person had reached normal objectives with close alignment to the his particular area of responsibility: retirement age subject to a interests of shareholders: the bonus payable is on a scale of maximum of 10 years additional pension arrangements which are 0-100% of salary and 50% of salary service, based on current appropriate to the relevant market: is payable for the achievement of pensionable salary: in the event of other benefits such as holidays and target business performance: death prior to retirement, sickness benefit which are cost- 80% of the bonus relates to the dependents are entitled to a effective and compatible with the achievement of the earnings per pension of two-thirds of the pension relevant national welfare arrangements: share target and 20% to the other that would have been earned had and performance measures: such person remained in service to share participation various plans age 62 plus a capital sum of four provide the opportunity for employees longer term incentive Executive times pensionable pay: pensions in to take a personal stake in the Directors are also rewarded for payment are increased annually in Companys wealth as shareholders.
improvement in the share price line with inflation, as measured by performance of the Company over a the UK Retail Prices Index, up to a The way in which these elements are period of years by the grant of share maximum of 5%: combined and applied varies depending, for options: the grant of options under the example, on market need and practice in AstraZeneca Share Option Plan is In respect of UK Executive Directors various countries.
determined by the Remuneration whose pensionable earnings are Committee, as are the performance capped by the earnings limit For each Executive Director, the individual targets that will apply and whether they imposed by the Finance Act 1989, components are: will apply to the grant and or exercise of unapproved defined contribution options this is described in more detail schemes are made available: annual salary the actual salary for each below: and currently, only the Chief Financial of the Executive Directors is determined Officer is affected by this limit: the by the Remuneration Committee on pension arrangements the table on Company has agreed to pay behalf of the Board: these salaries page 56 gives details of the changes in annually 50% of base salary in reflect the experience and sustained the value of the Executive Directors excess of the statutory earnings cap performance of the individuals to whom accrued pensions during 2003: for the pension and associated tax they apply, as judged annually by the liability, with the intention of Remuneration Committee, taking UK Executive Directors pension providing equivalence of benefits account also of market arrangements the Chief Executive with non-capped UK Executive competitiveness: is a member of the Companys main Directors: if this does not provide UK defined benefit pension plan: the equivalence, the Company has short term bonus: normal pension age under this plan agreed to make up the difference: is 62: however, a members accrued the benefits derived from the Chief Executive is eligible for an pension is available from age 60 equivalence are shown in the table annual bonus related solely to the without any actuarial reduction: in on page 56 as if the scheme was a achievement of the targeted addition the accrued pension is defined benefit arrangement: the performance of earnings per share: available, unreduced, from age 57 if Company contribution in 2003 in the bonus payable is on a scale of the Company consents to a request respect of the pension element was 0-100% of salary and 50% of salary for early retirement and from age 50 $193,000: is payable for the achievement of if the retirement is at the Companys target performance: as referred to request: AstraZeneca Annual Report and Directors Remuneration Report 52 Form 20-F Information 2003 Directors Remuneration Report continued Swedish Executive Directors In respect of bonuses in 2003, relevant The dilutive effect of the proposed grants of pension arrangements normally, factors considered included the delivery of options on the Companys issued share Swedish Executive Directors higher earnings per share than had been capital was also considered by the participate in the collectively anticipated both by the Board and Remuneration Committee, particularly in the bargained ITP pension plan, which externally at the start of the year, the sales light of the letter sent to shareholders in provides pensions, dependents performance of newer products, new 2000 by the then Chairman of the pensions and lump sums on death product approvals and emerging benefits Remuneration Committee ahead of the in service: in respect of those from efficiency and effectiveness projects.
approval of the plan at the AGM in which it Swedish Directors or former Going forward, the corporate goals will was stated that the percentage of the Directors, namely Hkan Mogren reflect the Companys statement that issued share capital which could be and ke Stavling, whose financial performance over the next several allocated under all of the Companys pensionable earnings are or were in years is likely to rank among the best in the employee share plans over a period of ten excess of the earnings limit imposed global peer group of large capitalisation years should be under 10%: this by the Swedish Communal Tax Law pharmaceutical companies.
commitment is applied by the Kommunalskattelagen, Remuneration Committee in practice as a supplementary pension AstraZeneca Share Option Plan limit, on average, of under 1% per annum.
commitments are made: the The AstraZeneca Share Option Plan was Company has agreed to pay 70% of approved at the AGM in 2000 following prior The Remuneration Committee concluded pensionable salary from age 60 to consultation with major shareholders.
Its that a grant of options to those plan age 65 and 50% of such earnings design took account of the overall participants and individual Executive from age 65: the ITP provisions are competitiveness of the Companys Directors proposed for a grant was included in this additional remuneration arrangements for senior appropriate given the level of performance commitment: paid in pension capital executives and US employees in the achieved.
may also be used in the event of context of the Companys peers in the retirement or termination before the pharmaceutical industry.
Since the Companys AGM in 2003, a age of 60: in the event of long term number of the Companys larger illness then a pension is payable The Remuneration Committee must on shareholders particularly those who immediately as if such person had every occasion, before agreeing the grant of expressed concern in respect of the reached the normal retirement age, options to Executive Directors and others, Directors Remuneration Report for 2002 of 70% of current pensionable be satisfied that the most recent and also have been consulted about the Companys salary: on death in retirement the the underlying performance of the Company remuneration arrangements for its accrued pension is payable to a justifies the grant: in addition it must be Executive Directors and senior employees, surviving spouse or other satisfied that the necessary performance including the Companys use of employee dependent: in the event of death has been achieved by each individual.
While there are no apparent prior to retirement the accrued concerns on the overall levels of pension is payable to a surviving In agreeing grants of options in 2003, the remuneration, concern has been expressed spouse or other dependent plus a Remuneration Committee took into about the fact that the AstraZeneca Share capital sum of three times account, in particular, very successful Option Plan currently involves the pensionable salary less $100,000 if progress in the previous year in the consideration of performance criteria on married or two times pensionable transformation of the Companys product grant, as described above, rather than the salary less $100,000 if not.
portfolio in view of the potential reduction in fulfilment of performance conditions before sales resulting from the loss of patent options can be exercised.
The dialogue with Other customary benefits such as a car and protection for key products.
In particular, in health benefits are also made available.
background of increased regulatory accordance with the arrangements agreed This happens by way of the Executive demands and costs, the Company had set with shareholders in 2000, the Directors participation in the Companys clear strategic targets to be achieved in the Remuneration Committee intends to review flexible benefits arrangements, which apply reference period: to increase sales of new the AstraZeneca Share Option Plan during to the vast majority of the Companys UK and growth products: to extend the 2004. and Swedish employees.
application of existing products: to launch new products and to achieve key A graph is set out on page 57 illustrating the Measurement of performance milestones in making further new products Companys total shareholder return TSR Each year, as referred to above both short ready for launch.
These targets were over the last five years against the FTSE 100 term and longer term objectives are agreed achieved.
For example: Nexium, launched Index.
Although the Company does not use with the Board and regularly monitored in in 2001, achieved sales of close to $2 billion TSR as a formal measure of performance respect of both individual business in 2002 and Seroquel reached sales of over for its share plans, it is an important functions and integrated corporate strategy.
$1 billion for the first time: new indications or measure used in the Companys overall Performance against these objectives formulations for Arimidex, Casodex and business performance assessment determines functional bonuses and, Zomig were launched in 2002: Iressa and process.
separately, whether or not share options will Faslodex were launched and key be granted.
milestones were passed in respect of Crestor and Exanta.
AstraZeneca Annual Report and Directors Remuneration Report Form 20-F Information 2003 53 Executive Directors service contracts the Company which is being paid on a Arrangements for Hkan Mogren The service contracts of the current monthly basis from his leaving date until ceasing to be an Executive Director Executive Directors provide for a notice the end of January 2005: the amount of From April 1999, Hkan Mogren was period of one year.
For new Executive this compensation is equivalent to two Executive Deputy Chairman of the Directors, the Board would aim to negotiate years base annual salary: Mr Stavling Company.
At the end of August 2003, he a one year notice period.
In exceptional was entitled to a notice period of two ceased to be an Executive Director and circumstances, the initial notice period may years under his service contract at the employee of the Company and became be for longer than one year.
In those time he left the Company.
As a circumstances, the Board would explain to result, certain arrangements concerning shareholders the reasons why it believed a All other allowances, bonuses and Dr Mogrens remuneration were considered longer notice period was necessary and it benefits ceased on Mr Stavling leaving and approved by the Remuneration would be the Boards intention that it should the Company at the end of January Committee, based on existing contracts be reduced to one year subsequently.
the time of the AGM on 29 April 2004, the unexpired term of Executive Directors On leaving the Company, options held From 1 January 2003 until 31 August service contracts will be a maximum of one by Mr Stavling over 80,516 Ordinary 2003, Dr Mogren received the year.
The details of the Executive Directors Shares in the Company vested and emoluments to which he was entitled as individual service contracts are set out in the became exercisable: these options had Executive Deputy Chairman, the details table below.
been granted to him since April 1999 at of which are disclosed on pages 55 and various prices in the normal course of 56 in the normal way: these included an In the event of the termination of an operation of the Zeneca 1994 Executive annual bonus which was calculated pro Executive Directors service contract, Share Option Scheme and the rata for the period of his employment by depending upon the circumstances the AstraZeneca Share Option Plan: if not the Company in 2003.
Company may be liable to provide exercised, they will lapse on 31 January compensation to the Executive Director 2005.
Following his change in status to Nonequivalent to the benefits which he or she Executive Deputy Chairman at the end would have received during the contractual In May 2003, there were released to Mr of August 2003, Dr Mogren is receiving notice period.
For current Executive Stavling from retention 7,624 Ordinary compensation from the Company which Directors, it is the Companys expectation Shares in the Company which he was is being paid on a monthly basis from 1 that any such liability would be calculated awarded in 2000 under the Zeneca September 2003 until the end of August on the basis of one years base salary, target Executive Performance Bonus Scheme 2004: the amount of this compensation bonus and other benefits.
The Companys in respect of his bonus for 1999. is equivalent to one years base annual policy in the event of the termination of an salary which is derived from his service Executive Directors service contract is to In November 2003, there were released contract.
avoid any liability to the Executive Director in to Mr Stavling 533 Ordinary Shares in excess of his or her contractual entitlement the Company which were allocated to All allowances, bonuses and benefits and aim to ensure that any liability is him in November 2000 on the demerger ended on Dr Mogren ceasing to be an mitigated to the fullest extent possible.
of Zeneca Agrochemicals in respect of Executive Director and employee of the executive share options he held on 10 Company at the end of August 2003 Leaving arrangements for ke Stavling November 2000. with the exception of his existing health ke Stavling, Executive Director, left the insurance cover and life insurance Company at the end of January 2003.
Share options held by Mr Stavling under arrangements which will continue until Mr Stavlings leaving arrangements were the Astra Shareholder Value Incentive age 60. considered and approved by the Plan were not affected by his leaving the Remuneration Committee, based on Company and details are disclosed on Although Dr Mogren ceased to be an existing contracts and practice.
These are page 59 in the normal way.
employee of the Company on 31 summarised below.
August 2003, he has continued as a From age 60, the pension arrangements Director of the Company and As disclosed in the Directors previously disclosed by the Company in consequently, under the relevant plan Remuneration Report for 2002, Mr respect of Mr Stavling will apply.
rules, options over Ordinary Shares Stavling is receiving compensation from previously granted to him at various Details of Executive Directors service contracts Executive Director Date of service contract Unexpired term at Notice period 31 December 2003 Sir Tom McKillop 11.01.96 One year One year Jonathan Symonds 20.05.98 One year One year AstraZeneca Annual Report and Directors Remuneration Report 54 Form 20-F Information 2003 Directors Remuneration Report continued prices in the normal course of operation the total amount of such fees paid to him of the Astra Shareholder Value Incentive was 49,000.
Plan, the Zeneca 1994 Executive Share Option Scheme and the AstraZeneca Jonathan Symonds, Chief Financial Officer, Share Option Plan were not affected by served as a Non-Executive Director of his change of status to Non-Executive QinetiQ Group plc throughout 2003 and Deputy Chairman.
retained the fees paid to him for this service.
In 2003, the total amount of such fees The same applies to both the Ordinary paid to him was 33,000.
With effect from Shares in the Company which he was 1 September 2003, Mr Symonds also awarded in 2000 under the Zeneca receives and retains fees of 15,000 per Executive Performance Bonus Scheme annum for his position as a member of the in respect of his bonus for 1999 and the UK Accounting Standards Board.
Ordinary Shares in the Company which were allocated to him in November Directors emoluments in 2003 2000 on the demerger of Zeneca The Directors emoluments in 2003 are Agrochemicals in respect of executive disclosed on pages 55 to 56. share options he held on 10 November 2000.
These Ordinary Shares were Directors interests in shares released to him in May and November Details of the Directors interests in the 2003 respectively.
More details about Companys Ordinary Shares are disclosed share options and the releases of shares on pages 57 to 59. are disclosed on pages 57 to 59.
Audit As a Non-Executive Director, Dr Mogren will The Directors emoluments in 2003 and the not be entitled to any future performance details of the Directors interests in the related bonuses, grants of share options Companys Ordinary Shares disclosed on or pension contributions.
From age 60, pages 55 to 59 have been audited by the subject to his re-election as a Director at Companys external auditor.
AGMs, Dr Mogrens fee as Non-Executive Deputy Chairman will be 100,000 per annum.
From age 60, the pension arrangements previously disclosed by the Company in respect of Dr Mogren will apply.
During 2003, Dr Mogren purchased certain furnishings from the Company on arms length terms.
The total value of the transaction concerned was SEK618,000.
The value of the items purchased was assessed by independent valuers.
Position of the Non-Executive Directors None of the Non-Executive Directors has a service contract.
They are not eligible for performance-related bonuses or the grant of share options.
No pension contributions are made on their behalf.
External appointments and retention of fees With the specific approval of the Board in each case, Executive Directors may accept external appointments as non-executive directors of other companies and retain any related fees paid to them.
Sir Tom McKillop, Chief Executive, served as a Non-Executive Director of Lloyds TSB Group plc throughout 2003 and retained the fees paid to him for this service.
In 2003, AstraZeneca Annual Report and Directors Remuneration Report Form 20-F Information 2003 55 Directors emoluments in 2003 The aggregate remuneration, excluding pension contributions, paid to or accrued for all Directors and officers of the Company for services in all capacities during the year ended 31 December 2003 was 11 million $18 million including 250,000 $403,000 to the Chairman.
Remuneration of individual Directors is set out below in sterling and US dollars.
Among those Directors who receive their remuneration in sterling are the Chairman, the Non-Executive Deputy Chairman, the senior Non-Executive Director, the Chief Executive and the Chief Financial Officer.
Salary Taxable Total Total Total and fees Bonuses benefits Other 2003 2002 2001 Sterling 000 000 000 000 000 000 000 Percy Barnevik 250 250 250 250 Hkan Mogren 461 450 51 284 1,246 1,347 1,104 Sir Tom McKillop 885 860 1 44 1,790 1,479 1,304 Jonathan Symonds 534 451 6 80 1,071 909 815 Sir Peter Bonfield 74 74 46 38 John Buchanan 53 53 33 Jane Henney 49 49 60 9 Karl von der Heyden 55 55 47 41 Michele Hooper 19 19 Joe Jimenez 19 19 Erna Mller 49 49 62 55 Dame Bridget Ogilvie 49 49 62 55 Marcus Wallenberg 46 46 42 38 Former Directors ke Stavling 81 6 402 489 835 712 Others 621 702 Total 2,624 1,761 64 810 5,259 5,793 5,123 Relates to relocation allowances: Payment for pension related tax liabilities: Includes settlement on retirement of accrued holiday entitlement: Includes provision for accommodation in the UK: Compensation payment and for accommodation related tax liabilities: Part year only.
Salary Taxable Total Total Total and fees Bonuses benefits Other 2003 2002 2001 US dollars $000 $000 $000 $000 $000 $000 $000 Percy Barnevik 403 403 373 368 Hkan Mogren 743 725 82 458 2,008 2,010 1,623 Sir Tom McKillop 1,427 1,387 1 71 2,886 2,208 1,918 Jonathan Symonds 861 727 9 129 1,726 1,357 1,199 Sir Peter Bonfield 119 119 68 56 John Buchanan 86 86 49 Jane Henney 79 79 90 13 Karl von der Heyden 89 89 70 60 Michele Hooper 31 31 Joe Jimenez 31 31 Erna Mller 79 79 93 81 Dame Bridget Ogilvie 79 79 93 81 Marcus Wallenberg 74 74 63 56 Former Directors ke Stavling 131 9 648 788 1,246 1,047 Others 927 1,032 Total 4,232 2,839 101 1,306 8,478 8,647 7,534 Relates to relocation allowances: Payment for pension related tax liabilities: Includes settlement on retirement of accrued holiday entitlement: Includes provision for accommodation in the UK: Compensation payment and for accommodation related tax liabilities: Part year only.
As described in the previous section, compensation payments to Hkan Mogren and ke Stavling were 225,000 $363,000 and 399,000 $643,000 respectively and are included within Other in the above tables.
AstraZeneca Annual Report and Directors Remuneration Report 56 Form 20-F Information 2003 Directors Remuneration Report continued Directors emoluments in 2003 continued The remuneration of Directors is or was in the case of former Directors with minor exceptions established and paid in either Swedish kronor or sterling and has been converted into US dollars in the second table on page 55 at the average exchange rate for the year in question.
These rates were: GBP USD SEK USD 2001 0.68 10.79 2002 0.67 9.86 2003 0.62 8.30 Some Directors and officers were also granted options to subscribe for Ordinary Shares under the Companys share option plans.
Details of share options granted to, and exercised by, Directors and the aggregate of gains realised on exercised options in the year are given on pages 58 and 59.
No Director or officer has a family relationship with any other Director or officer.
Transactions with Directors During the year there were no material recorded transactions between the Company and the Directors.
Executive Directors Sir Tom McKillop Jonathan Symonds Hkan Mogren ke Stavling Pension Arrangements $000 $000 $000 $000 per annum Defined Benefit Arrangements 1.
Increase in accrued pension during year as a result of inflation 24 9 20 3.
Adjustment to accrued pension as a result of salary increase relative to inflation 2 1 4.
Increase in accrued pension as a result of additional service 28 18 5.
Change in transfer value during the period less employee contributions 1,728 513 841 27 9 10 11 10.
Pensionable service years 34 23 30 30 12 12 12 Accrued pension payable between the age of 60 and 65.
Once 65 the pension payable is reduced by 2 7ths or 28.6% from the figures shown.
On leaving service at 31 August 2003 On leaving service at 31 January 2003 Pensions are payable to Directors in either Swedish kronor or sterling.
For ease of understanding, the whole table has been presented using the exchange rates for 2003 set out above.
AstraZeneca Annual Report and Directors Remuneration Report Form 20-F Information 2003 57 Graph showing total shareholder return The UK Directors Remuneration Report Regulations 2002 require the inclusion in the Directors Remuneration Report of a graph showing total shareholder return TSR over a five year period in respect of a holding of the Companys shares, plotted against TSR in respect of a hypothetical holding of shares of a similar kind and number by reference to which a broad equity market index is calculated.
This illustrates the Companys TSR performance against the broad equity market index selected.
For the purposes of this graph, set out below, we have selected the FTSE 100 Index as the appropriate index.
Graph showing total shareholder return 1 January 1999 31 December 2003 AstraZeneca FTSE100 140 120 100 80 60 Jan 99 Jan 00 Jan 01 Jan 02 Jan 03 Dec 03 Source: Thomson Financial Datastream Directors interests in shares The interests at 31 December 2003 or on date of retirement of the persons who on that date were Directors including the interests of their families in shares and debentures of AstraZeneca PLC are shown below, all of which were beneficial except as otherwise stated.
None of the Directors has a beneficial interest in the shares of any of the Companys subsidiaries.
Interest in Interest in Ordinary Shares, Ordinary Shares, including shares Shares held including shares Shares held held in trust, in trust at held in trust, in trust at at 1 Jan 2003 1 Jan 2003 Net shares at 31 Dec 2003 31 Dec 2003 or appointment or appointment acquired or resignation or resignation date date disposed date date Percy Barnevik 100,000 50,000 50,000 Hkan Mogren 65,974 10,234 3,810 62,164 Sir Tom McKillop 74,443 13,424 3,392 77,835 Jonathan Symonds 13,828 7,788 2,899 10,929 Sir Peter Bonfield 500 500 John Buchanan 500 500 Jane Henney 500 500 Karl von der Heyden 20,000 20,000 Michele Hooper 500 500 Joe Jimenez 500 500 Erna Mller 2,718 2,718 Dame Bridget Ogilvie 500 500 Marcus Wallenberg 74,504 74,504 Former Directors ke Stavling 9,139 8,157 9,139 8,157 No Director or senior executive beneficially owns, or has options over, 1% or more of the outstanding shares of the Company, nor do they have different voting rights to other shareholders.
Shares held in trust at 1 January 2003 above include both long term incentive bonus shares appropriated under the Zeneca Executive Performance Bonus Scheme and also shares allocated on the demerger of Zeneca Agrochemicals, in respect of executive share options held on 10 November 2000.
In respect of the latter, the shares were released and became beneficially owned by Directors on 13 November 2003.
AstraZeneca Annual Report and Directors Remuneration Report 58 Form 20-F Information 2003 Directors Remuneration Report continued Directors interests in shares continued The interests of Directors and former Directors in options to subscribe for Ordinary Shares of the Company, which include options granted under the AstraZeneca Savings-Related Share Option Scheme, together with options granted and exercised during the year are included in the following table: Exercise Market price No.
First and last exercise dates of groups of options, within which periods there are shorter exercise periods.
AstraZeneca Annual Report and Directors Remuneration Report Form 20-F Information 2003 59 In addition to the above, the following Directors or former Directors held options under the Astra Shareholder Value Incentive Plan which were converted into options over AstraZeneca shares on completion of the merger based on an exchange ratio of 0.5045 AstraZeneca options for each Astra option held.
No further options have been or will be granted under the scheme: Astra SVIP Options Exercise Market price No.
of shares price at date of First date Last date under option per share exercise exercisable exercisable Hkan Mogren At 1 Jan 2003 25,080 389.68SEK 06.04.99 23.01.06 market price above option price market price below option price 25,080 389.68SEK 06.04.99 23.01.06 Sold 8,792 316.13SEK 358.00SEK 06.04.99 09.01.04 At 31 Dec 2003 16,288 429.38SEK 06.04.99 23.01.06 market price above option price market price below option price 16,288 429.38SEK 06.04.99 23.01.06 ke Stavling At 1 Jan 2003 8,143 429.38SEK 06.04.99 23.01.06 market price above option price market price below option price 8,143 429.38SEK 06.04.99 23.01.06 At 31 Jan 2003 8,143 429.38SEK 06.04.99 23.01.06 market price above option price market price below option price 8,143 429.38SEK 06.04.99 23.01.06 Exercise prices are weighted averages.
The aggregate amount of gains made by Directors on the exercise of share options during the year amounted to $0.5 million 2002 $0.4 million, 2001 $0.02 million and the gains made by the highest paid Director were $470,000 2002 $nil, 2001 $13,000.
The market price of shares trading on the London Stock Exchange at 31 December 2003 was 2680 pence and the range during 2003 was 1820 pence to 2868 pence.
The market price of shares trading on the Stockholm Stock Exchange at 31 December 2003 was 350.50 SEK and the range during 2003 was 245.00 SEK to 382.00 SEK.
The Register of Directors Interests which is open to inspection contains full details of Directors shareholdings and options to subscribe for Ordinary Shares.
On behalf of the Board G H R Musker Group Secretary and Solicitor 29 January 2004
